Patents by Inventor Monika Ermann

Monika Ermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for treatment of diseases related to DUX4 expression
    Publication number: 20220226318
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: January 13, 2022
    Publication date: July 21, 2022
    Applicant: Facio Intellectual Property B.V.
    Inventors: Joris De Maeyer, Marcus Geese, Martin Schneider, Sebastian Monecke, Alexander Kaever, Monika Ermann, Timothy Robin James
  • Compounds for treatment of diseases related to DUX4 expression
    Publication number: 20210177847
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 17, 2021
    Applicant: Facio Intellectual Property B.V.
    Inventors: Joris De Maeyer, Marcus Geese, Martin Schneider, Sebastian Monecke, Alexander Kaever, Monika Ermann, Timothy Robin James
  • Compounds for treatment of diseases related to DUX4 expression
    Patent number: 10973820
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: April 13, 2021
    Assignee: Facio Intellectual Property B.V.
    Inventors: Joris de Maeyer, Marcus Geese, Martin Schneider, Sebastian Monecke, Alexander Kaever, Monika Ermann, Timothy Robin James
  • Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases
    Patent number: 10472341
    Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: November 12, 2019
    Assignees: APEIRON BIOLOGICS AG, EVOTEC SE
    Inventors: Monika Ermann, Guenther Lametschwandtner, Patricia Leonie Amouzegh, Russell Stuart Craft, Thomas Hanke, Timothy Robin James, Severine Danielle Jones, Hans Loibner, Pui Leng Loke, Ina Sternberger, Anton Stuetz, Roland Wehr, Mark Whittaker
  • Compounds for treatment of diseases related to DUX4 expression
    Publication number: 20190175596
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 13, 2019
    Applicant: Facio Intellectual Property B.V.
    Inventors: Joris de Maeyer, Marcus Geese, Martin Schneider, Sebastian Monecke, Alexander Kaever, Monika Ermann, Timothy Robin James
  • BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES
    Publication number: 20180170888
    Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 21, 2018
    Inventors: Monika ERMANN, Guenther LAMETSCHWANDTNER, Patricia Leonie AMOUZEGH, Russell Stuart CRAFT, Thomas HANKE, Timothy Robin JAMES, Severine Danielle JONES, Hans LOIBNER, Pui Leng LOKE, Ina STERNBERGER, Anton STUETZ, Roland WEHR, Mark WHITTAKER
  • Deubiquitinase inhibitors and methods for use of the same
    Patent number: 9868736
    Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB) by contact with a compound of formula (I).
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: January 16, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Nicholas J. Donato, Moshe Talpaz, Luke Peterson, Matthew Young, Hollis D. Showalter, Christiane Wobus, Mary Xuan Dziem O'Riordan, Monika Ermann
  • DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME
    Publication number: 20160237082
    Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB) by contact with a compound of formula (I)
    Type: Application
    Filed: October 10, 2014
    Publication date: August 18, 2016
    Inventors: Nicholas J. Donato, Moshe Talpaz, Luke Peterson, Matthew Young, Hollis D. Showalter, Christiane Wobus, Mary Xuan Dziem O'Riordan, Monika Ermann
  • Compounds which modulate the CB2 receptor
    Patent number: 9315454
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: April 19, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Angela Berry, Doris Riether, Monika Ermann, James Edward Jenkins, Innocent Mushi
  • Amine and ether compounds which modulate the CB2 receptor
    Patent number: 8957063
    Abstract: Compounds which modulate the CB2 receptor are disclosed. The compounds are useful for treating CB2 receptor-mediated diseases such as pain.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: February 17, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Pier Francesco Cirillo, Eugene Richard Hickey, Doris Riether, Monika Ermann, Innocent Mushi
  • Sulfonyl compounds which modulate the CB2 receptor
    Patent number: 8846936
    Abstract: Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: September 30, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Eugene Richard Hickey, Doris Riether, Monika Ermann
  • Compounds which modulate the CB2 receptor
    Patent number: 8829034
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: September 9, 2014
    Assignee: Boehringer Ingerlheim International GmbH
    Inventors: Angela Berry, Pier Francesco Cirillo, Eugene Richard Hickey, Doris Riether, David Thomson, Renee M. Zindell, Nigel Blumire, Chandana Parke, Monika Ermann, James Edward Jenkins, Innocent Mushi, Christopher Francis Palmer, Malcolm Taylor
  • Compounds which selectively modulate the CB2 receptor
    Patent number: 8735430
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: May 27, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Eugene Richard Hickey, Doris Riether, Lifen Wu, Renee M. Zindell, Nigel James Blumire, Monika Ermann, Edward Thomas Glenn, Someina Khor, Przemyslaw Zawadzki
  • SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR
    Publication number: 20130184315
    Abstract: Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Application
    Filed: July 18, 2011
    Publication date: July 18, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GmbH
    Inventors: Eugene Richard Hickey, Doris Riether, Monika Ermann
  • Compounds which selectively modulate the CB2 receptor
    Patent number: 8383651
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: February 26, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Doris Riether, Renee M. Zindell, Patricia Amouzegh, Nigel James Blumire, Monika Ermann, Innocent Mushi, Robert John Scott
  • Compounds which selectively modulate the CB2 receptor
    Patent number: 8372874
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: February 12, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Eugene Richard Hickey, Doris Riether, Lifen Wu, Renee M. Zindell, Monika Ermann
  • Therapeutic uses of compounds which selectively modulate the CB2 receptor
    Patent number: 8362039
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: January 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Angela Berry, Eugene Richard Hickey, Markus Ostermeier, Doris Riether, Achim Sauer, David Smith Thomson, Lifen Wu, Renee M. Zindell, Patricia Amouzegh, Nigel James Blumire, Stephen Peter East, Monika Ermann, Someina Khor, Innocent Mushi
  • Therapeutic uses of compounds which selectively modulate the CB2 receptor
    Patent number: 8349871
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: January 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Angela Berry, Eugene Richard Hickey, Doris Riether, Achim Sauer, David Smith Thomson, Lifen Wu, Renee M. Zindell, Patricia Amouzegh, Nigel James Blumire, Stephen Peter East, Monika Ermann, Someina Khor, Innocent Mushi
  • COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR
    Publication number: 20120316173
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Application
    Filed: January 11, 2011
    Publication date: December 13, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Alessandra Bartolozzi, Angela Berry, Doris Riether, Monika Ermann, James Edward Jenkins, Innocent Mushi
  • Tetrazole compounds which selectively modulate the CB2 receptor
    Patent number: 8329735
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: December 11, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Monika Ermann, Doris Riether, Renee M. Zindell